Emily Kent
Communications, Dalton Agency
Replay available
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) Q4 2025 earnings conference call, held 2026-03-03. Replay captured from the company's public earnings webcast.

Communications, Dalton Agency
Chief Executive Officer
Vice President, Organizational Development
Chief Financial Officer
Good afternoon and welcome to Cumberland Pharmaceutical 2025 Financial Report and Company Update. This call is being recorded at the company's request and will be archived on its website for one year from today's date. I'd like to turn it over to Emily Kent from Dalton Agency who handles Cumberland's communications. Emily, please proceed. Thank you, everyone, and thank you for joining us today. This afternoon, Cumberland issued a press release announcing its annual and fourth quarter financial results. The release also provided an overall company update, including key developments during the year. The release, which includes the related financial tables, can be found on the company's website at www.cumberlandpharma.com. During today's call, management will share an overview of those financial results. and a company update, including a recent development and a discussion of Cumberland's brands, pipeline, and partners. Participating in today's call are A.J. Kazemi, Cumberland's Chief Executive Officer, Todd Anthony, Vice President, Organizational Development, and John Hamm, Chief Financial Officer. Please keep in mind that their discussions may include some forward-looking statements as defined in the Private Security Reform Act. Those statements reflect the company's current views and expectations concerning future events and may involve risks as well as uncertainties. There are many factors that could affect Cumberland's future results, including natural disasters, economic downturns, international conflicts, trade restrictions, public health epidemics, and others that are beyond the company's control. Those issues are described under the caption risk factors in Cumberland's annual report on Form 10-K and any subsequent updates filed with the SEC. Any forward-looking...